$6.29
2.33% day before yesterday
Nasdaq, Dec 27, 10:00 pm CET
ISIN
US00650F1093
Symbol
ADPT

Adaptive Biotechnologies Corp Stock price

$6.29
+0.56 9.77% 1M
+2.83 81.79% 6M
+1.39 28.37% YTD
+1.18 23.09% 1Y
-20.59 76.60% 3Y
-22.98 78.51% 5Y
-13.71 68.55% 10Y
Nasdaq, Closing price Fri, Dec 27 2024
-0.15 2.33%
ISIN
US00650F1093
Symbol
ADPT
Sector
Industry

Key metrics

Market capitalization $928.27m
Enterprise Value $909.27m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 5.13
P/S ratio (TTM) P/S ratio 5.24
P/B ratio (TTM) P/B ratio 4.15
Revenue growth (TTM) Revenue growth -1.34%
Revenue (TTM) Revenue $177.28m
EBIT (operating result TTM) EBIT $-166.27m
Free Cash Flow (TTM) Free Cash Flow $-114.54m
Cash position $243.33m
EPS (TTM) EPS $-1.34
P/E forward negative
P/S forward 5.22
EV/Sales forward 5.12
Short interest 8.34%
Show more

Is Adaptive Biotechnologies Corp a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Adaptive Biotechnologies Corp Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Adaptive Biotechnologies Corp forecast:

6x Buy
75%
2x Hold
25%

Analyst Opinions

8 Analysts have issued a Adaptive Biotechnologies Corp forecast:

Buy
75%
Hold
25%

Financial data from Adaptive Biotechnologies Corp

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
177 177
1% 1%
100%
- Direct Costs 87 87
8% 8%
49%
90 90
6% 6%
51%
- Selling and Administrative Expenses 139 139
5% 5%
79%
- Research and Development Expense 97 97
7% 7%
55%
-146 -146
12% 12%
-82%
- Depreciation and Amortization 20 20
31% 31%
11%
EBIT (Operating Income) EBIT -166 -166
15% 15%
-94%
Net Profit -195 -195
0% 0%
-110%

In millions USD.

Don't miss a Thing! We will send you all news about Adaptive Biotechnologies Corp directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Adaptive Biotechnologies Corp Stock News

Neutral
GlobeNewsWire
21 days ago
New data demonstrate the actionability of clonoSEQ for tailoring treatment decisions in patients with MCL, CLL, MM and ALL
Neutral
GlobeNewsWire
26 days ago
SEATTLE, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, announced that its next-generation sequencing (NGS)-based clonoSEQ® test for measurable residual disease (MRD) assessment will be included i...
Positive
Seeking Alpha
about one month ago
Adaptive Biotechnologies posted strong Q3 results, beating expectations and reducing losses, while management has done a good job of reducing quarterly cash burn rates. The company's MRD segment, driven by clonoSEQ, continues to show significant growth, and the company's balance sheet remains strong. An updated analysis around Adaptive Biotechnologies follows in the paragraphs below.
More Adaptive Biotechnologies Corp News

Company Profile

Adaptive Biotechnologies Corp. engages in the development of an immune medicine platform. It harnesses the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its products and services include immunoSEQ, clonoSEQ, cellular therapy, and vaccines. The company was founded by Chad Robins, Harlan Robins, and Chris Carlson in September 2009 and is headquartered in Seattle, WA.

Head office United States
CEO Chad Robins
Employees 709
Founded 2009
Website www.adaptivebiotech.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today